Feng Min, Gao Jun, Sui Nan, Li Ming
Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China.
Psychopharmacology (Berl). 2015 Apr;232(7):1219-30. doi: 10.1007/s00213-014-3756-2. Epub 2014 Oct 7.
Acute administration of clozapine (a gold standard of atypical antipsychotics) disrupts avoidance response in rodents, while repeated administration often causes a tolerance effect.
The present study investigated the neuroanatomical basis and receptor mechanisms of acute and repeated effects of clozapine treatment in the conditioned avoidance response test in male Sprague-Dawley rats.
2,5-dimethoxy-4-iodo-amphetamine (DOI, a preferential 5-HT2A/2C agonist) or quinpirole (a preferential dopamine D2/3 agonist) was microinjected into the medial prefrontal cortex (mPFC) or nucleus accumbens shell (NAs), and their effects on the acute and long-term avoidance disruptive effect of clozapine were tested.
Intra-mPFC microinjection of quinpirole enhanced the acute avoidance disruptive effect of clozapine (10 mg/kg, sc), while DOI microinjections reduced it marginally. Repeated administration of clozapine (10 mg/kg, sc) daily for 5 days caused a progressive decrease in its inhibition of avoidance responding, indicating tolerance development. Intra-mPFC microinjection of DOI at 25.0 (but not 5.0) μg/side during this period completely abolished the expression of clozapine tolerance. This was indicated by the finding that clozapine-treated rats centrally infused with 25.0 μg/side DOI did not show higher levels of avoidance responses than the vehicle-treated rats in the clozapine challenge test. Microinjection of DOI into the mPFC immediately before the challenge test also decreased the expression of clozapine tolerance.
Acute behavioral effect of clozapine can be enhanced by activation of the D2/3 receptors in the mPFC. Clozapine tolerance expression relies on the neuroplasticity initiated by its antagonist action against 5-HT2A/2C receptors in the mPFC.
急性给予氯氮平(非典型抗精神病药物的金标准)会破坏啮齿动物的回避反应,而反复给药通常会产生耐受效应。
本研究在雄性Sprague-Dawley大鼠的条件性回避反应试验中,探究氯氮平治疗急性和反复效应的神经解剖学基础及受体机制。
将2,5-二甲氧基-4-碘苯丙胺(DOI,一种选择性5-HT2A/2C激动剂)或喹吡罗(一种选择性多巴胺D2/3激动剂)微量注射到内侧前额叶皮质(mPFC)或伏隔核壳(NAs),并测试它们对氯氮平急性和长期回避破坏效应的影响。
向mPFC内微量注射喹吡罗可增强氯氮平(10mg/kg,皮下注射)的急性回避破坏效应,而注射DOI则使其略有降低。每天皮下注射氯氮平(10mg/kg),连续5天,会导致其对回避反应的抑制作用逐渐减弱,表明产生了耐受。在此期间,向mPFC内微量注射25.0(而非5.0)μg/侧的DOI可完全消除氯氮平耐受的表达。这一发现表明,在氯氮平激发试验中,经中央注入25.0μg/侧DOI的氯氮平处理大鼠,其回避反应水平并不高于溶剂处理大鼠。在激发试验前立即向mPFC内注射DOI也可降低氯氮平耐受的表达。
mPFC中D2/3受体的激活可增强氯氮平的急性行为效应。氯氮平耐受的表达依赖于其对mPFC中5-HT2A/2C受体的拮抗作用引发的神经可塑性。